A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer

Yuh Min Chen, Reury Perng Perng, Kuang Yao Yang, Tsang Wu Liu, Chun Ming Tsai, Jacqueline Ming-Liu, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Study objective: Vinorelbine and gemcitabine are two active single agents used in the treatment of non-small cell lung cancer (NSCLC). A clinical thai was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in patients with inoperable (stage IIIB or IV) NSCLC. Design: A multicenter phase II study. Vinorelbine, 20 mg/m, was given as a 10-min IV infusion, followed by a 30-min IV infusion of gemcitabine, 800 mg/m2, on days 1, 8, and 15 of each 28-day cycle. Patients and measurements: From March 1998 to August 1998, 40 patients were enrolled in the study. The efficacy and toxicity of the treatment were recorded. Results: All patients are evaluable for treatment response and toxicity profile. Two patients achieved a complete response, and 27 patients achieved a partial response, with an overall response rate of 72.5% (95% confidence interval, 58.7 to 86.3%). Median survival time was 11 months. The significant (World Health Organization grade, 3/4) toxicities were myelosuppression, including leukopenia (47.5% of patients), anemia (17.5% of patients), and thrombocytopenia (12.5% of patients). However, febrile neutropenia occurred in three patients and accounted for one treatment-related death. Fatigue, or flu-like syndrome, occurred in 17 patients, and the symptoms were reversed spontaneously 1 to 2 days after injection in 10 patients. Another seven patients needed dose reduction to ameliorate symptoms. Interstitial pneumonitis occurred in six patients who recovered after steroid treatment. No patient suffered from grade 3 or 4 nausea/vomiting. Conclusion: The combination of vinorelbine and gemcitabine in patients with advanced NSCLC is a highly active non-cisplatin-containing regimen with an acceptable toxicity profile.

Original languageEnglish
Pages (from-to)1583-1589
Number of pages7
JournalChest
Volume117
Issue number6
DOIs
Publication statusPublished - Jan 1 2000
Externally publishedYes

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
vinorelbine

Keywords

  • Gemcitabine
  • Non-small cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer. / Chen, Yuh Min; Perng, Reury Perng; Yang, Kuang Yao; Liu, Tsang Wu; Tsai, Chun Ming; Ming-Liu, Jacqueline; Whang-Peng, Jacqueline.

In: Chest, Vol. 117, No. 6, 01.01.2000, p. 1583-1589.

Research output: Contribution to journalArticle

Chen, Yuh Min ; Perng, Reury Perng ; Yang, Kuang Yao ; Liu, Tsang Wu ; Tsai, Chun Ming ; Ming-Liu, Jacqueline ; Whang-Peng, Jacqueline. / A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer. In: Chest. 2000 ; Vol. 117, No. 6. pp. 1583-1589.
@article{527a9c92d1d848ef9e3fef906f1ca89e,
title = "A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer",
abstract = "Study objective: Vinorelbine and gemcitabine are two active single agents used in the treatment of non-small cell lung cancer (NSCLC). A clinical thai was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in patients with inoperable (stage IIIB or IV) NSCLC. Design: A multicenter phase II study. Vinorelbine, 20 mg/m, was given as a 10-min IV infusion, followed by a 30-min IV infusion of gemcitabine, 800 mg/m2, on days 1, 8, and 15 of each 28-day cycle. Patients and measurements: From March 1998 to August 1998, 40 patients were enrolled in the study. The efficacy and toxicity of the treatment were recorded. Results: All patients are evaluable for treatment response and toxicity profile. Two patients achieved a complete response, and 27 patients achieved a partial response, with an overall response rate of 72.5{\%} (95{\%} confidence interval, 58.7 to 86.3{\%}). Median survival time was 11 months. The significant (World Health Organization grade, 3/4) toxicities were myelosuppression, including leukopenia (47.5{\%} of patients), anemia (17.5{\%} of patients), and thrombocytopenia (12.5{\%} of patients). However, febrile neutropenia occurred in three patients and accounted for one treatment-related death. Fatigue, or flu-like syndrome, occurred in 17 patients, and the symptoms were reversed spontaneously 1 to 2 days after injection in 10 patients. Another seven patients needed dose reduction to ameliorate symptoms. Interstitial pneumonitis occurred in six patients who recovered after steroid treatment. No patient suffered from grade 3 or 4 nausea/vomiting. Conclusion: The combination of vinorelbine and gemcitabine in patients with advanced NSCLC is a highly active non-cisplatin-containing regimen with an acceptable toxicity profile.",
keywords = "Gemcitabine, Non-small cell lung cancer, Vinorelbine",
author = "Chen, {Yuh Min} and Perng, {Reury Perng} and Yang, {Kuang Yao} and Liu, {Tsang Wu} and Tsai, {Chun Ming} and Jacqueline Ming-Liu and Jacqueline Whang-Peng",
year = "2000",
month = "1",
day = "1",
doi = "10.1378/chest.117.6.1583",
language = "English",
volume = "117",
pages = "1583--1589",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer

AU - Chen, Yuh Min

AU - Perng, Reury Perng

AU - Yang, Kuang Yao

AU - Liu, Tsang Wu

AU - Tsai, Chun Ming

AU - Ming-Liu, Jacqueline

AU - Whang-Peng, Jacqueline

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Study objective: Vinorelbine and gemcitabine are two active single agents used in the treatment of non-small cell lung cancer (NSCLC). A clinical thai was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in patients with inoperable (stage IIIB or IV) NSCLC. Design: A multicenter phase II study. Vinorelbine, 20 mg/m, was given as a 10-min IV infusion, followed by a 30-min IV infusion of gemcitabine, 800 mg/m2, on days 1, 8, and 15 of each 28-day cycle. Patients and measurements: From March 1998 to August 1998, 40 patients were enrolled in the study. The efficacy and toxicity of the treatment were recorded. Results: All patients are evaluable for treatment response and toxicity profile. Two patients achieved a complete response, and 27 patients achieved a partial response, with an overall response rate of 72.5% (95% confidence interval, 58.7 to 86.3%). Median survival time was 11 months. The significant (World Health Organization grade, 3/4) toxicities were myelosuppression, including leukopenia (47.5% of patients), anemia (17.5% of patients), and thrombocytopenia (12.5% of patients). However, febrile neutropenia occurred in three patients and accounted for one treatment-related death. Fatigue, or flu-like syndrome, occurred in 17 patients, and the symptoms were reversed spontaneously 1 to 2 days after injection in 10 patients. Another seven patients needed dose reduction to ameliorate symptoms. Interstitial pneumonitis occurred in six patients who recovered after steroid treatment. No patient suffered from grade 3 or 4 nausea/vomiting. Conclusion: The combination of vinorelbine and gemcitabine in patients with advanced NSCLC is a highly active non-cisplatin-containing regimen with an acceptable toxicity profile.

AB - Study objective: Vinorelbine and gemcitabine are two active single agents used in the treatment of non-small cell lung cancer (NSCLC). A clinical thai was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in patients with inoperable (stage IIIB or IV) NSCLC. Design: A multicenter phase II study. Vinorelbine, 20 mg/m, was given as a 10-min IV infusion, followed by a 30-min IV infusion of gemcitabine, 800 mg/m2, on days 1, 8, and 15 of each 28-day cycle. Patients and measurements: From March 1998 to August 1998, 40 patients were enrolled in the study. The efficacy and toxicity of the treatment were recorded. Results: All patients are evaluable for treatment response and toxicity profile. Two patients achieved a complete response, and 27 patients achieved a partial response, with an overall response rate of 72.5% (95% confidence interval, 58.7 to 86.3%). Median survival time was 11 months. The significant (World Health Organization grade, 3/4) toxicities were myelosuppression, including leukopenia (47.5% of patients), anemia (17.5% of patients), and thrombocytopenia (12.5% of patients). However, febrile neutropenia occurred in three patients and accounted for one treatment-related death. Fatigue, or flu-like syndrome, occurred in 17 patients, and the symptoms were reversed spontaneously 1 to 2 days after injection in 10 patients. Another seven patients needed dose reduction to ameliorate symptoms. Interstitial pneumonitis occurred in six patients who recovered after steroid treatment. No patient suffered from grade 3 or 4 nausea/vomiting. Conclusion: The combination of vinorelbine and gemcitabine in patients with advanced NSCLC is a highly active non-cisplatin-containing regimen with an acceptable toxicity profile.

KW - Gemcitabine

KW - Non-small cell lung cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0034047923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034047923&partnerID=8YFLogxK

U2 - 10.1378/chest.117.6.1583

DO - 10.1378/chest.117.6.1583

M3 - Article

VL - 117

SP - 1583

EP - 1589

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -